Molecular pathways: Cachexia signaling - A targeted approach to cancer treatment

Clinical Cancer Research

Volumn 22, Issue 16, 2016, Pages 3999-4004

  Miyamoto, Yuji ^a   Hanna, Diana L ^a   Zhang, Wu ^a   Baba, Hideo ^b   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ANAMORELIN; BIMAGRUMAB; CLAZAKIZUMAB; DOCETAXEL; ENOBOSARM; ETANERCEPT; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; LANDOGROZUMAB; MAMMALIAN TARGET OF RAPAMYCIN; MEGESTROL ACETATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MABP1; MYOSTATIN; PLACEBO; PROTEIN KINASE B; SMAD PROTEIN; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTOKINE;

ADVANCED CANCER; ARTICLE; CACHEXIA; COLORECTAL CANCER; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LUNG CANCER; MOLECULAR MECHANICS; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; NON SMALL CELL LUNG CANCER; NONHUMAN; NUTRITIONAL SUPPORT; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SKELETAL MUSCLE; ANIMAL; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; TRANSLATIONAL RESEARCH;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS; CACHEXIA; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; MOLECULAR TARGETED THERAPY; MUSCLE DEVELOPMENT; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NEOPLASMS; PROTEOLYSIS; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84982179484     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0495     Document Type: Article

References (54)

1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489-95.
2. Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ 1997;315:1219-22.
3. Wigmore SJ, Plester CE, Richardson RA, Fearon KC. Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 1997; 75:106-9.
4. Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998;34:503-9.
5. Biolo G, Cederholm T, Muscaritoli M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. Clin Nutr 2014;33:737-48.
6. Tisdale MJ. Reversing cachexia. Cell 2010;142:511-2.
7. Han HQ, Zhou X, Mitch WE, Goldberg AL. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol 2013;45:2333-47.
8. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 2012;16:153-66.
9. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82:373-428.
10. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S, et al. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 2007;6:472-83.
11. Hasselgren PO, Wray C, Mammen J. Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem Biophys Res Commun 2002;290:1-10.
12. Narsale AA, Carson JA. Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care 2014;8:321-7.
13. Li YP, Reid MB. NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol 2000;279:R1165-70.
14. Garcia-Martinez C, Lopez-Soriano FJ, Argiles JM. Acute treatment with tumour necrosis factor-alpha induces changes in protein metabolism in rat skeletal muscle. Mol Cell Biochem 1993;125:11-8.
15. Fong Y, Moldawer LL, Marano M, Wei H, Barber A, Manogue K, et al. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol 1989;256:R659-65.
16. Li YP, Schwartz RJ, Waddell ID, Holloway BR, Reid MB. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J 1998;12: 871-80.
17. Hunter RB, Stevenson E, Koncarevic A, Mitchell-Felton H, Essig DA, Kandarian SC. Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy. FASEB J 2002;16:529-38.
18. Cai D, Frantz JD, Tawa NEJr, Melendez PA, Oh BC, Lidov HG, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004;119:285-98.
19. Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.AmJ Physiol Endocrinol Metab 2012;303: E410-21.
20. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90.
21. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004;350:2682-8.
22. Chen YG, Lui HM, Lin SL, Lee JM, Ying SY. Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med (Maywood) 2002;227:75-87.
23. Chen YG, Wang Q, Lin SL, Chang CD, Chuang J, Ying SY. Activin signaling and its role in regulation of cell proliferation, apoptosis, and carcinogenesis. Exp Biol Med (Maywood) 2006;231:534-44.
24. Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R, et al. Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol 2009;296:C1248-57.
25. Sacheck JM, Ohtsuka A, McLary SC, Goldberg AL. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophyrelated ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 2004;287:E591-601.
26. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/ mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001;3:1009-13.
27. Izumiya Y, Hopkins T, Morris C, Sato K, Zeng L, Viereck J, et al. Fast/ glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab 2008;7:159-72.
28. Calnan DR, Brunet A. The FoxO code. Oncogene 2008;27:2276-88.
29. Sartori R, Gregorevic P, Sandri M. TGFbeta and BMP signaling in skeletal muscle: potential significance for muscle-related disease. Trends Endocrinol Metab 2014;25:464-71.
30. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 2009;296: C1258-70.
31. Lok C. Cachexia: the last illness. Nature 2015;528:182-3.
32. Argiles JM, Lopez-Soriano FJ. Catabolic proinflammatory cytokines. Curr Opin Clin Nutr Metab Care 1998;1:245-51.
33. Torelli GF, Meguid MM, Moldawer LL, Edwards CKIII, Kim HJ, Carter JL, et al. Use of recombinant human soluble TNF receptor in anorectic tumorbearing rats. Am J Physiol 1999;277:R850-5.
34. Jatoi A, Dakhil SR, Nguyen PL, Sloan JA, Kugler JW, Rowland KMJr, et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia/ weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer 2007;110:1396-403.
35. Jatoi A, Ritter HL, Dueck A, Nguyen PL, Nikcevich DA, Luyun RF, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer 2010;68:234-9.
36. Wiedenmann B, Malfertheiner P, Friess H, Ritch P, Arseneau J, Mantovani G, et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008;6:18-25.
37. Johnston AJ, Murphy KT, Jenkinson L, Laine D, Emmrich K, Faou P, et al. Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival. Cell 2015;162:1365-78.
38. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, et al. MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol 2014;15:656-66.
39. Fisher GA. A phase III study of xilonix in refractory colorectal cancer patients with weight loss. J Clin Oncol 33, 2015(suppl 3; abstr 685).
40. Clarke SJ, Smith JT, Gebbie C, Sweeney C, Olszewski N. A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. J Clin Oncol 27:15s, 2009(suppl; abstr 3025).
41. Rigas JR, Schuster M, Orlov SV, Milovanovic B, Prabhash K, Smith JT, et al. Effect of ALD518, a humanized anti-IL-6 antibody, on lean bodymass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): results of a phase II randomized, double-blind safety and efficacy trial. J Clin Oncol 28:15s, 2010(suppl; abstr 7622).
42. Schuster M, Rigas JR, Orlov SV, Milovanovic B, Prabhash K, Smith JT, et al. ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): results of a phase II, randomized, double-blind, placebo-controlled trial. J Clin Oncol 28:15s, 2010(suppl; abstr 7631).
43. Padrao AI, Oliveira P, Vitorino R, Colaco B, Pires MJ, Marquez M, et al. Bladder cancer-induced skeletal muscle wasting: disclosing the role of mitochondria plasticity. Int J Biochem Cell Biol 2013;45: 1399-409.
44. Loumaye A, de Barsy M, Nachit M, Lause P, Frateur L, van Maanen A, et al. Role of activin A and myostatin in human cancer cachexia. J Clin Endocrinol Metab 2015;100:2030-8.
45. Busquets S, Toledo M, Orpi M, Massa D, Porta M, Capdevila E, et al. et al. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle 2012;3:37-43.
46. Benny Klimek ME, Aydogdu T, Link MJ, Pons M, Koniaris LG, Zimmers TA. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun 2010;391:1548-54.
47. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010;142:531-43.
48. Murphy KT, Chee A, Gleeson BG, Naim T, Swiderski K, Koopman R, et al. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am J Physiol Regul Integr Comp Physiol 2011;301:R716-26.
49. Jameson GS, Von Hoff DD, Weiss GJ, Richards DA, Smith DA, Becerra C, et al. Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer. J Clin Oncol 30, 2012 (suppl; abstr 2516).
50. Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 2014;83:2239-46.
51. Aversa Z, Bonetto A, Penna F, Costelli P, Di Rienzo G, Lacitignola A, et al. et al.Changes in myostatin signaling in non-weight-losing cancer patients. Ann Surg Oncol 2012;19:1350-6.
52. Gallot YS, Durieux AC, Castells J, Desgeorges MM, Vernus B, Plantureux L, et al. et al.Myostatin gene inactivation prevents skeletal muscle wasting in cancer. Cancer Res 2014;74:7344-56.
53. Toledo M, Busquets S, Penna F, Zhou X, Marmonti E, Betancourt A, et al. Complete reversal of muscle wasting in experimental cancer cachexia: additive effects of activin type II receptor inhibition and beta-2 agonist. Int J Cancer 2016;138:2021-9.
54. Mori S, Matsuzaki K, Yoshida K, Furukawa F, Tahashi Y, Yamagata H, et al. TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 2004;23: 7416-29.